Demis Hassabis: The CEO Working to Solve Cancer With AI

Company Mission & Vision - Isomorphic Labs' mission is to solve all disease by building a general platform to understand biology and chemistry [1][2] - The company aims to revolutionize drug discovery and potentially discover hundreds of cures by focusing on platform capabilities [20] - The long-term vision includes expanding into areas like energy and material design to address climate and energy crises [22] Drug Discovery & Development - Isomorphic Labs is currently at the preclinical stage and building a team for the clinical phase [3] - Internal pipeline focuses on oncology and immunology, particularly cancer, due to clinical favorability for new drugs [5][6] - The company aims to significantly reduce preclinical research time from 3-6 years to a matter of months [7] - While focusing on drug discovery, the company plans to partner for the clinical and regulatory phases [9][10] Partnerships & Funding - Isomorphic Labs has partnerships with Novartis and Eli Lilly to refine its platform [11][12] - The partnership with Novartis expanded from 3 to 6 targets [13] - The company raised $600 million USD in its first external funding round to build out the platform and attract talent [14] Technology & Innovation - Isomorphic Labs is building upon work with AlphaFold, extending beyond protein structure to chemistry, compound design, and toxicity [4][17][18] - The company is taking a multi-modal approach, developing specialized models adapted to specific scientific areas [19][23]